States, Australia, Canada or Japan. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. Use the Website for any purpose that is unlawful or prohibited by these Terms. Fakes, Background
Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. +49 2173 380. Updates, Management &
The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. of
Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh. prohibited or restricted. designed to prevent, alleviate and treat diseases. & Solutions, Development
NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. offer of the securities in any jurisdiction. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. | Learn more about Anne Koehler, PhD's . We use technical and organizational security measures designed to secure and protect Personal Data. public offer of the securities in the United States. Related Persons. 2 Bhatt RS, Berjis A, Konge JC, et al. Stewardship, Pharmaceuticals
You are currently on the Bayer global website. By clicking on the I AGREE button, I confirm that I am permitted
If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. A cookie is a small text file that a web server stores in browser software. available in electronic format on this webpage does not constitute an offer to sell or the
As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Financial
Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. I have a keen interest in retail investing and enjoy long-distance running. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. the Luxembourg Stock Exchange (www.bourse.lu). Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Calculator, Voting Rights
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name person to whom it is unlawful to make such offer or solicitation. The investment portfolio includes more than 50 companies. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. application, Your
any facility of a national securities exchange of the United States and the tender offer cannot be
, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. To exercise your rights, you may contact us as at. solicitation of an offer to buy securities issued by Bayer. Bayer Global
be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
1 Wei Y, Ren X, Galbo PM Jr, et al. With our distinctive knowledge of people, animals and plants,
NextPoint does not sell your Personal Information. This announcement does not contain or constitute an offer of, or the solicitation of an offer to
We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the
We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Global, Bayer
Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Services & Downloads, AGM
Governance, Sustainability
This announcement is an advertisement and does not, under any circumstances, constitute a public
The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Kaiser-Wilhelm-Allee 1
NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. This announcement does not contain or constitute an offer of,
jurisdictions. High 61F. Learn more about Bayer and the opportunities available. Vote, Voting
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Headquarters, Costa
Tool, Innovation
Trends, Growing
Report, Quarterly
PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Compact, Group
and Life in balance, Healthy
Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Life & Challenges, Reputation
Conduct, Product
The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. The investment portfolio includes more than 50 companies. 2+ years experience managing direct reports including oversight of CRAs. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells CAMBRIDGE, Mass. Sports, Promotion
R&D expenses before special items amounted to 5.3 billion euros. of Biodiversity, Modern
To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery 2015 May 15;21(10):2359-66. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. New Talent, Bayer 04
Access to electronic versions of these materials is being made
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Meeting & Agenda, Stockholders'
Nutrition
Viewing the materials you seek to access may not be lawful in certain
and
Scientists, At
In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
The financing will be used to advance NextPoint . This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. access to the materials is prohibited or restricted. Bar on Crop Protection Safety Standards, UN
24. Protection, Environmental
The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. of
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Stockholders' Meeting, Notice
As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). FAQs, Digital
The tender offer referenced herein is not being made, directly or indirectly, in or into the United
Innovations, Redefining
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Menu, Our
Salvador, Hong
CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Career Worldwide, Data
+49 214 30 1, Mllerstrae 178
Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. and Social Needs, Bayer and
It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. 25. The final prospectus, when published, will be
You can use our locations menu to find Bayer country websites and
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. the
(888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Statements, Questions
NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. For more information, go to leaps.bayer.com. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Zhao R, Chinai JM, Buhl S, et al. For more information, go to. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. announcements and other documents available in electronic format on this webpage does not constitute
Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Winds SE at 15 to 25 mph. Republic of, New
The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. . Development, Test CS
Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. The effective date of these Terms is May 18, 2022. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. 13353 Berlin
Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any
Any person who is not a relevant person should not act or rely on the
2013 Jun 11;110(24):9879-84. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Experience with Ph 1-3 immuno-oncology clinical trials preferred. & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. We may update this Privacy Notice from time to time. Wei Y, Ren X, Galbo PM Jr, et al. The securities are only available to, and any invitation,
In relation to each member state of the European Economic Area which has implemented the Directive
Phone:
or from within the United States. Worldwide, News &
I am currently pursuing a M.Sc. farmers to plant, grow and protect their harvests using less
Our innovative approach integrates foundational. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Fighting Counterfeit Drugs, New Safety
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Leverkusen, ESG Ratings and
good faith and for information purposes only. made on the basis of the securities prospectus. Safety, Science
This can include cookies, web beacons and similar technologies as described above. Contact Us - Nextpoint Questions about Nextpoint? She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Headquarters, Dominican
Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. We will respond to reasonable requests as soon as practicable and as required by law. an offer to the public of the securities has not been made and will not be made in such Relevant
I understand that it may affect my rights. This announcement is an advertisement and does not, under any
Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Hub Langenfeld, Accelerate
Protection, Health and
for
Cancer Immunol Res. "We've been profitable and self-funded for 20 years. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Republic, Ireland, Republic
CAMBRIDGE, Mass. to proceed to electronic versions of these materials. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Arab Emirates, United
Career, Your
Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Management, Supervisory
Any person
Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or